Structure Therapeutics (GPCR) risk factors

Item 1A of every Structure Therapeutics Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.

Open GPCR in Gloom →

Structure Therapeutics' chart, financials and news, free in your browser.Open GPCR in Gloom →

FY2025 10-K risk factors
93 risks13 new9 dropped17 reworded
Structure Therapeutics expanded its pipeline to include five early-stage clinical candidates: aleniglipron, ACCG-2671, ANPA-0073, LTSE-2578, and ACCG-3535. The company added specific risks regarding Chinese regulatory requirements, Australian tax credits, and SEC personnel disruptions.
Filed Feb 26, 2026
FY2024 10-K risk factors
89 risks
Structure Therapeutics relies heavily on unproven platform technology and third-party manufacturers for early-stage clinical candidates like aleniglipron.
Filed Feb 27, 2025